; and (3) not later than 1 year after the date of enactment of this Act, report to the Congress on the progress made in implementing paragraphs (1) and (2). (e) GAO study and recommendations on inclusion of information on drug-Gene interactions on drug labels Not later than 180 days after the date of enactment of this Act, the Comptroller General of the United States shall— (1) study, and formulate recommendations on, how the Food and Drug Administration can include and update information on drug-gene interactions on drug labels; and (2) submit recommendations to the relevant committees of jurisdiction. (f) Report on additional improvements to electronic health record systems (1) In general Not later than 180 days after the date of enactment of this Act, the Secretary shall— (A) complete a report on additional improvements to electronic health record systems that are needed to further the development of real world evidence (as defined in section 505F of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355g )) in pharmacogenomics; and (B) submit such report to the Congress. (2) Consideration of needed advancements As part of the report under paragraph (1), the Secretary shall consider what advancements are needed in electronic health record systems to capture information about the laboratory and the test used as part of pharmacogenomic testing.